Share
Dr. Nicholas Botwood
Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company developing innovative cancer therapies, has appointed Dr. Nicholas Botwood, BSc (Hons), MBBS, MFPM, FRCP, as Head of Research and Development (R&D) and Chief Medical Officer.
Dr. Botwood succeeds Dr. Neil Gallagher, who is departing to pursue new opportunities, and will be responsible for driving the company’s R&D strategy and development efforts.
Dr. Botwood brings more than 25 years of industry experience, most recently serving as Senior Vice President, Head of Worldwide Medical Oncology at Bristol Myers Squibb, where he led all medical activities for the oncology portfolio, including new asset launches, data generation, medical education, and commercial strategy.
From 2020 to 2022, he served as Senior Vice President, Head U.S. Medical at Bristol Myers Squibb, overseeing medical strategy in the United States across commercial and development in hematology and oncology. Between 2015 and 2020, he held senior clinical development roles at the company, including Head of Oncology Clinical Development and Development Team Lead. Earlier in his career, Dr. Botwood spent over a decade at AstraZeneca, serving as Vice President, Head of Oncology Clinical and Head of Global Clinical Operations.
Dr. Botwood earned his Bachelor of Medicine and Bachelor of Surgery (MBBS) from Imperial College London and a Bachelor of Science (BSc) from University College London. He is a member of the Faculty of Pharmaceutical Medicine and an elected Fellow of the Royal College of Physicians UK.
